Quest Enters Breast-Cancer Test Market Dominated by Myriad (1) - Businessweek

[INCIID News Feed]

<img alt="" height="1" width="1" />
Quest Enters Breast-Cancer Test Market Dominated by Myriad (1)
Businessweek
Quest Diagnostics Inc. (DGX:US), the biggest U.S. operator of medical labs, will sell a test for two breast cancer genes starting today, providing competition for Myriad Genetics Inc. (MYGN:US) and potentially helping to reduce costs for women fearful they are ...
Who Can Challenge Myriad&#39;s Monopoly In Breast Cancer Gene Tests?Chicago Tribune
Quest Diagnostics Offers Genetic Test At Discount to RivalWall Street Journal
Quest Diagnostics Introduces BRCAvantage(TM), Broadly Expanding Patient ...MarketWatch
WHTC
all 16 news articles &raquo;


More...